Our specialists have expertise in prescribing not only the core medications used to treat inflammatory bowel disease (IBD), including antibiotics, aminosalicylates (5-ASAs), and steroids, but also using immune modulators such as mercaptopurine, azathioprine, methotrexate and cyclosporine.

In addition, our specialists have a great deal of experience with biologic therapies and other newly approved therapies such as infliximab (Remicade), adalimumab (Humira), certolizumab (Cimzia), golimumab (Simponi), vedolizumab (Entyvio), ustekinumab (Stelara), tofacitinib (Xeljanz), and natalizumab (Tysabri), and offer an on-site infusion center. Physicians may use one of two approaches to treatment: "step-up" method, which starts with milder drugs first, or a "top-down" method, which prescribes stronger drugs earlier in the treatment process.

Our gastroenterologists also have ongoing clinical trials of investigational agents not yet approved by the Food and Drug Administration.

For more detailed information on medicines used to treat IBD, please see the "Treatment Options In IBD" (page 25) section of the IBD Program Patient Information Guide.

IBD Research and Clinical Trials

Person touching an image of a stomach
The University of Maryland Inflammatory Bowel Disease (IBD) Research Program is a national leader in clinical research.